SCHEMBL26837606

SCHEMBL26837606

COc1ccc2oc(Br)c(CCBr)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ HPGD P15428 4/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ CASP3 P42574 1/20 0.50
▸ SENP8 Q96LD8 1/20 0.50
▸ SENP7 Q9BQF6 1/20 0.50
▸ SENP6 Q9GZR1 1/20 0.50
▸ NQO1 P15559 1/20 0.47
▸ HSD17B10 Q99714 3/20 0.45
▸ DYRK1A Q13627 1/20 0.44
▸ MAOA P21397 1/20 0.44
▸ PPARG P37231 1/20 0.43
▸ MTNR1A P48039 7/20 0.43
▸ MTNR1B P49286 7/20 0.43
▸ TP53 P04637 2/20 0.42
▸ LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26837607 0.76 MAOA (0.54) KDM4EALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL27470491 0.75 DYRK1A (0.70) KDM4EALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL18045173 0.73 ALDH1A1 (0.77) KDM4EALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL6217970 0.72 MTNR1A (0.64) ALDH1A1MTNR1AMTNR1BLMNAHTT
SCHEMBL9119624 0.71 SMN1; SMN2 (0.54) KDM4EALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL26837593 0.71 PLK1 (0.40) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL25318719 0.69 MAPT (0.51) KDM4EALDH1A1NPC1MAPTRAB9A
SCHEMBL8707352 0.68 DYRK1A (0.74) KDM4EALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL13564007 0.67 ALDH1A1 (0.61) KDM4EALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL29619913 0.67 ALDH1A1 (1.00) KDM4EALDH1A1HPGDSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382919-A1 OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-11-30 — — US disclosed
US-20230382919-A1 OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382919-A1 OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS GRIA4, GRIA3, GRIN3A KDM4E 2836/4885ALDH1A1 2437/4885HPGD 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback